WebJul 15, 2024 · The INBUILD® trial was a randomized, double-blind, placebo-controlled, parallel-group phase III trial of 663 patients, conducted at 153 sites in 15 countries, which evaluated the efficacy, safety, and tolerability of nintedanib (150 mg, twice daily) over 52 weeks in patients with progressive fibrosing ILD. 2 Eligible patients were aged ≥ 18 ... WebApr 5, 2024 · Study record managers: ... Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK; INBUILD Trial Investigators. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2024 Oct 31;381(18):1718-1727. doi: 10.1056/NEJMoa1908681. Epub 2024 Sep 29. ...
Eric Matteson, ACR 2024: Long-term nintedanib treatment for …
WebBackground: The INBUILD trial investigated the efficacy and safety of nintedanib versus placebo in patients with progressive fibrosing interstitial lung diseases (ILDs) other than … WebA subgroup analysis of patients with autoimmune-related ILD from the INBUILD trial was conducted that demonstrated among 170 subjects with autoimmune disease-related ILDs, the rate of decline in FVC over 52 weeks was −75.9 ml/year with nintedanib versus −178.6 ml/year with placebo . The findings of the INBUILD trial raise an important point ... how to switch between windows
Nintedanib in patients with progressive fibrosing …
WebThe INBUILD trial was a randomized, double-blind, placebo-controlled, parallel group trial conducted at 153 sites in 15 countries that evaluated the efficacy and safety tolerability of … WebApr 8, 2024 · Study Description Go to Brief Summary: This center intends to conduct a single-center, randomized, placebo-controlled study to evaluate the effectiveness and safety of Nintedanib ethanesulfonate soft capsule in the treatment of pulmonary fibrosis in patients with moderate to severe COVID-19. Detailed Description: WebMar 25, 2024 · Nintedanib remains an important treatment option for patients with idiopathic pulmonary fibrosis and is the first drug to be approved for use in patients with other chronic fibrosing ILDs with a progressive phenotype and SSc-ILD. ... INBUILD Part A encompassed the first 52 weeks of the trial; Part B was a variable treatment period … how to switch bills into tenants name